Call Us: 1.800.873.5297

By

New Studies Reveal Effects of Testosterone Therapy

Two recent studies have shed some light on the effects that testosterone replacement therapies have on men. In particular, the studies revealed that exercise and obesity significantly impact the success rate of testosterone replacement therapy.

Dr. Min Gu Park from Inje University in South Korea conducted a study, which demonstrated that exercise may influence the positive effects of testosterone therapy. His study consisted of 50 men with late-onset hypogonadism (i.e., low testosterone). The subjects were divided into two groups and each group received testosterone replacement therapy over a 12-week period followed by eight weeks without receiving any treatment. The first group of subjects received an exercise program while the second group of subjects did not. The first group’s exercise regimen consisted of 90 minutes aerobic, strength, and stretching exercises for at least 3 days a week over the 12-week period. The results revealed that while both groups had an increase in testosterone levels, the exercise group showed significantly higher levels. The findings also demonstrated that the improvement of testosterone levels could be maintained with continuous exercise after testosterone treatments have ended.

Another study conducted by Cornell Medical College revealed that men with diabetes and obesity have a lower success rate with testosterone treatment than other men who have clinically labeled non-obese body mass indexes (BMI). The study included 58 participants. Of those patients, 32 had a BMI rating that labeled them non-obese while 26 men were obese. All the subjects were similar in age and had about the same baseline hormone levels at the start of the study. The subjects also had similar symptoms associated with low testosterone, such as low sex drive and erectile dysfunction. The subjects received one out of three commercial transdermal testosterone replacements over 18 to 24 months. By the end of the study, findings showed 81% of the non-obese men achieved normal testosterone levels and 52% of the obese men achieved normal levels. Dr. Tobias Kohler, associate professor and residency program director at Southern Illinois University School of Medicine, concluded that “as these studies show, not all men may be good candidates for this therapy.”

Other medical professional criticize low testosterone replacement therapies. Dr. Ajay Nangia, Professor of Urology at the University of Kansas, states that doctors and patients rely too much on testosterone products to deal with issues like low libido and infertility. Dr. Nangia adds, “there are some legitimate concerns about testosterone therapy,” so there is a need for more research and studies to be conducted to learn more about them.

These worries follow the FDA’s January 31, 2014 Safety Announcement that it will investigate the cardiovascular risks associated with testosterone therapy after growing concern that these drugs may be linked to increased risk of blood clots, heart attack, and stroke, as demonstrated by published studies. The first study that prompted FDA’s Safety Announcement was published in the Journal of the American Medical Association (JAMA) in November 2013 and suggested that testosterone replacement drugs may increase the risk of heart attack, stroke and death. The study followed more than 8,000 male veterans with low testosterone. After comparing cardiovascular events in males taking a testosterone supplement with those who were not taking such supplements, the study concluded that men who used a supplement were 29% more likely to die, have a heart attack, or experience a stroke within three years of use. This was the result even after considering various factors that contribute to cardiovascular illnesses, such as age, blood pressure, and existing heart disease. The second study that prompted FDA’s Safety Announcement was published in the online journal PLos ONE on January 29, 2014, and concluded that older men, and younger men with pre-existing diagnosed heart disease, have an increased risk of heart attack following initiation of testosterone therapy. In particular, the study reported that men ages 65 years or older have a two-fold increase in the risk of heart attack in the first 90 days following the first prescription of testosterone therapy. And among younger men less than 65 years of age who have a pre-existing history of heart disease, the study reported a two- to three-fold increased risk of heart attack in the first 90 days following the first prescription of testosterone therapy.

The attorneys at Schlichter, Bogard & Denton, LLP are offering a free case review with no further obligation to those who have suffered injuries after using testosterone therapy. If you suffered injuries after using testosterone therapy, please contact the attorneys at Schlichter, Bogard & Denton, LLP toll-free at 1-800-873-5297 for your confidential and free consultation.

 

The choice of a lawyer is an important decision and should not be based solely on advertisements.

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.